Jun A S, Trounce I A, Brown M D, Shoffner J M, Wallace D C
Department of Genetics and Molecular Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Mol Cell Biol. 1996 Mar;16(3):771-7. doi: 10.1128/MCB.16.3.771.
A heteroplasmic G-to-A transition at nucleotide pair (np) 14459 within the mitochondrial DNA (mtDNA)-encoded NADH dehydrogenase subunit 6 (ND6) gene has been identified as the cause of Leber hereditary optic neuropathy (LHON) and/or pediatric-onset dystonia in three unrelated families. This ND6 np 14459 mutation changes a moderately conserved alanine to a valine at amino acid position 72 of the ND6 protein. Enzymologic analysis of mitochondrial NADH dehydrogenase (complex I) with submitochondrial particles isolated from Epstein-Barr virus-transformed lymphoblasts revealed a 60% reduction (P < 0.005) of complex I-specific activity in patient cell lines compared with controls, with no differences in enzymatic activity for complexes II plus III, III and IV. This biochemical defect was assigned to the ND6 np 14459 mutation by using transmitochondrial cybrids in which patient Epstein-Barr virus-transformed lymphoblast cell lines were enucleated and the cytoplasts were fused to a mtDNA-deficient (p 0) lymphoblastoid recipient cell line. Cybrids harboring the np 14459 mutation exhibited a 39% reduction (p < 0.02) in complex I-specific activity relative to wild-type cybrid lines but normal activity for the other complexes. Kinetic analysis of the np 14459 mutant complex I revealed that the Vmax of the enzyme was reduced while the Km remained the same as that of wild type. Furthermore, specific activity was inhibited by increasing concentrations of the reduced coenzyme Q analog decylubiquinol. These observations suggest that the np 14459 mutation may alter the coenzyme Q-binding site of complex I.
线粒体DNA(mtDNA)编码的NADH脱氢酶亚基6(ND6)基因中核苷酸对(np)14459处的异质性G到A转变,已被确定为三个不相关家族中Leber遗传性视神经病变(LHON)和/或小儿期肌张力障碍的病因。该ND6 np 14459突变使ND6蛋白第72位氨基酸处一个中度保守的丙氨酸变为缬氨酸。对从爱泼斯坦 - 巴尔病毒转化的淋巴母细胞中分离的亚线粒体颗粒进行线粒体NADH脱氢酶(复合体I)的酶学分析显示,与对照组相比,患者细胞系中复合体I的特异性活性降低了60%(P < 0.005),而复合体II加III、III和IV的酶活性没有差异。通过使用转线粒体杂种细胞,将患者爱泼斯坦 - 巴尔病毒转化的淋巴母细胞系去核,然后将细胞质体与线粒体DNA缺陷(p0)的淋巴母细胞样受体细胞系融合,将这种生化缺陷归因于ND6 np 14459突变。携带np 14459突变的杂种细胞相对于野生型杂种细胞系,其复合体I特异性活性降低了39%(p < 0.02),但其他复合体的活性正常。对np 14459突变的复合体I进行动力学分析表明,该酶的Vmax降低,而Km与野生型相同。此外,还原型辅酶Q类似物癸基泛醇浓度增加会抑制特异性活性。这些观察结果表明,np 14459突变可能改变复合体I的辅酶Q结合位点。